Form 4: Iovance Biotherapeutics Executive Raj K. Puri Reports Stock Transactions
SEC Form 4 Filing
Raj K. Puri, Chief Regulatory Officer of Iovance Biotherapeutics, reports the vesting of restricted stock units and subsequent withholding of shares for tax obligations.
Summary
- On December 16, 2024, Raj K. Puri, Chief Regulatory Officer of Iovance Biotherapeutics, had 8,334 restricted stock units (RSUs) vest.
- The company withheld 3,759 shares at a price of $7.84 to cover mandatory tax obligations.
- Following these transactions, Puri directly owns 155,412 shares of Iovance Biotherapeutics common stock and 8,334 restricted stock units.
- The remaining RSUs will vest in equal quarterly installments.
Sentiment
Score: 5
Explanation: This is a neutral report on standard executive compensation practices; it doesn't inherently indicate positive or negative sentiment.
Future Outlook
The remaining RSUs will vest in equal quarterly installments.
Industry Context
This Form 4 filing is a routine disclosure of insider transactions, providing transparency to investors regarding the actions of company executives.
Stakeholder Impact
- Shareholders are informed about executive compensation and stock ownership.
- Employees may be interested in the details of RSU vesting and tax implications.
Key Dates
| Date | Description |
|---|---|
| 2022-03-14 | Date of grant for the restricted stock units. |
| 2024-12-16 | Date of transaction: vesting of RSUs and withholding of shares for taxes. |
| 2024-12-18 | Date of signature for the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.